NextCure, Inc. (NXTC) - Q3 2024 10-Q Summary
Business Context and Reporting Period
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer patients, utilizing antibody-drug conjugates (ADCs), antibodies, and proteins. The company is headquartered in Beltsville, Maryland, and trades on the Nasdaq Global Select Market under the symbol NXTC. This report covers the quarterly period ended September 30, 2024. NextCure has not generated any revenue from product sales to date and expects to continue incurring operating losses as it advances its clinical programs.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(11.54) million | $(14.30) million | $(44.05) million | $(48.26) million |
| Net Loss Per Share | $(0.41) | $(0.51) | $(1.58) | $(1.73) |
| Operating Expenses | $12.50 million | $15.62 million | $47.29 million | $51.85 million |
| Cash & Cash Equivalents | $27.70 million (as of Sept 30, 2024) | |||
| Marketable Securities | ||||
| Total Liquidity | $75.31 million | |||
| Accumulated Deficit | $(368.53) million |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $3.12 million (20%) for the three months ended September 30, 2024, compared to the same period in 2023. This was driven by a $2.24 million decrease in Research and Development (R&D) and a $0.88 million decrease in General and Administrative (G&A) expenses.
- Restructuring Impact: The company recorded $2.54 million in restructuring and asset impairment charges during the nine months ended September 30, 2024. This included $0.7 million in severance costs and $1.8 million in asset impairments related to the March 2024 decision to pause internal manufacturing and reduce the workforce by approximately 37%. No such charges were recorded in the prior year periods.
- Liquidity Position: Cash and cash equivalents increased from $13.08 million at year-end 2023 to $27.70 million at September 30, 2024. However, total marketable securities decreased from $95.22 million to $47.61 million as the company utilized investments to fund operations.
- Collaboration Adjustments: Under the collaboration agreement with LigaChem, the company recorded cost-sharing reductions of $1.7 million for the nine months ended September 30, 2024, reflecting the 50-50 cost-sharing terms for the LNCB74 program.
Outlook, Management Commentary, and Risks
- Pipeline Prioritization: Management has prioritized two main programs: NC410 (ovarian and colorectal cancer) and LNCB74 (B7-H4 ADC). The company plans to file an Investigational New Drug (IND) application for LNCB74 by year-end 2024. For NC410, the company is closing out the Phase 1b/2 study and seeking partners or third-party financing to advance further.
- Non-Oncology Programs: The company is seeking partners for non-oncology programs NC181 (Alzheimer's disease) and NC605 (osteogenesis imperfecta), with potential IND filings within 12-18 months if funding is secured.
- Liquidity Runway: Management believes existing cash, cash equivalents, and marketable securities ($75.3 million) are sufficient to fund planned operations into the second half of 2026.
- Emerging Growth Company Status: NextCure will cease to be an Emerging Growth Company (EGC) effective December 31, 2024, requiring compliance with all applicable SEC requirements for non-EGCs starting with the next Form 10-K.
- Risks: Key risks include the need for additional financing to continue operations, the uncertainty of clinical trial results, and the potential inability to secure partnerships for non-priority programs. The company has a full valuation allowance against deferred tax assets due to its history of losses.
Investor Verification Checklist
- Verify the timeline and regulatory status of the planned IND filing for LNCB74 by year-end 2024.
- Monitor progress on securing partnerships or financing for the NC410, NC525, NC318, NC181, and NC605 programs.
- Track the burn rate and cash runway to confirm the ability to fund operations through the second half of 2026 without dilutive capital raises.
- Review the status of the LigaChem collaboration and the commercialization potential of the LNCB74 co-development product.
- Assess the impact of the March 2024 restructuring on the company's ability to execute its streamlined clinical strategy.